In connection with the implementation of the project under the working title ‘Design and development of nanoparticle-RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids’, by BS Biotechna SA (hereinafter referred to as the Ordering Party), for which the Ordering Party is applying for funding under the Competition for the development of targeted or personalised medicine based on medicinal products based on nucleic acids and small molecule compounds No. ABM/ 2022/6 conducted by the Medical Research Agency, the Ordering Party announces a procedure for the performance of basic research services concerning the characterisation of four new lipoplexes as intracellular RNA carriers and the design, synthesis and testing of the biological activity of siRNA molecules targeting a selected series of genes (maximum 25) associated with cancer development in a cellular system.
Attachments to download:
Market research_1_2023 (DOCX, 776 KB)
Offer form 1/2023 (DOCX, 251 KB)
NDA version 1 (DOCX, 211 KB)
NDA vbersion 2 (DOCX, 226 KB)